menu
    • menu
    [{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CV6 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"CV6 Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CV6 Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"5-Fluorouracil","moa":"","graph1":"Technology","graph2":"Approved","graph3":"CV6 Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"CV6 Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CV6 Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by CV6 Therapeutics

    Menu

    CV6 Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CV6 Therapeutics

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed

                            CV6 Therapeutics

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CV6-168,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CV6 Therapeutics Doses First Patient in Phase 1a Study of dUTPase Inhibitor CV6-168

                            Details : CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase. It is being investigated in combination with fluorouracil in cancer patients.

                            Brand Name : CV6-168

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 15, 2024

                            Lead Product(s) : CV6-168,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CV6 Therapeutics

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed

                            CV6 Therapeutics

                            United Kingdom arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CV6-168,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            CV6 Therapeutics Receives MHRA Approval for Novel Cancer Therapy Phase 1a Clinical Trial

                            Details : CV6-168 is a first-in-class DNA uracilation agent that selectively targets the enzyme dUTPase.

                            Brand Name : CV6-168

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 14, 2023

                            Lead Product(s) : CV6-168,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth